ArticleFrontiers in immunology2025
Mesoporous silica nanoparticles loaded Au nanodots: a self-amplifying immunotherapeutic depot for photothermal immunotherapy.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Photothermal therapy (PTT) has emerged as a highly promising approach for cancer treatment due to its advantages of localized treatment, controllable irradiation, and non-invasive nature. This study presents a multifunctional platform for tumor PTT based on Au nanoparticles-decorated mesoporous silica nanoparticles (MSN@Au), aiming to synergize photothermal ablation with immune modulation. Methods: MSN@Au nanoparticles were engineered as the PTT agent. Photothermal efficiency was evaluated under 808 nm near-infrared (NIR) laser irradiation. Anti-tumor efficacy was systematically assessed both in vitro (tumor cell cultures) and in vivo (tumor-bearing animal models). Immune responses were analyzed by examining immunogenic cell death (ICD) induction, dendritic cell maturation, and cytotoxic T cell activation/infiltration within the tumor microenvironment (TME). Results: MSN@Au demonstrated exceptional photothermal conversion efficiency under NIR irradiation, leading to significant tumor cell inhibition in both Discussion: This study underscores that the strategic design of MSN@Au as a PTT agent successfully induces ICD while modulating the immunosuppressive TME, significantly amplifying therapeutic efficacy. The integration of efficient photothermal ablation with immune activation opens new avenues for developing next-generation nanoplatforms that synergize PTT with immune modulation, offering a promising strategy for treating solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.